Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01823549 · ClinicalTrials.gov registry record
Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 109
- Enrollment target
NCT01823549: Completed study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01823549 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01823549 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
This study was a survey to determine the frequency of Complementary and Alternative Medicine (CAM) use in patients recently diagnosed with breast or prostate cancer who were starting radiation therapy. The survey was repeated at three time points to assess changes in CAM use over time.
Primary Outcome
Quantitate the various types of CAM therapy utilized by men with prostate cancer and women with breast cancer who are currently undergoing radiation therapy at The James Cancer Hospital and Solove Research Institute. Nutrient supplements and alternative medication use is the primary focus of the assessment.
Interventions
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2002-12-11 |
| Est. Completion | 2024-12-31 |
What the finished NCT01823549 record still lists
NCT01823549 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which questionnaire administration is the first listed.
NCT01823549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01823549 about?
NCT01823549 is a clinical study titled "Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients". This study was a survey to determine the frequency of Complementary and Alternative Medicine (CAM) use in patients recently diagnosed with breast or prostate cancer who were starting radiation therapy. The survey was repeated at three time points to assess changes in CAM use over time.
What is the current status of trial NCT01823549?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2002-12-11. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT01823549?
The interventions under investigation include: questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01823549?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI